Ambrisentan

安立生坦

Report date: 2024/02/21 12:26:30
NME

Base Information

Drug NameAmbrisentan
Drug Alias Nameambrisentanum安贝生坦安倍生坦安博森坦安博生坦 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEndothelin receptor type A antagonists
TargetsEndothelin receptor type A
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)HypoxiaAscites +[16] 
Global Approved IndicationsPulmonary Arterial Hypertension
Approved Indications in ChinaPulmonary Arterial Hypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2007/06/15
Country/TerritoryCzechiaBelgiumCanada +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAbbott Laboratories
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcGlaxosmithkline (Ireland) LtdGilead Sciences Inc +[5] 
Inactive CompaniesAugusta UniversityMedical University Of GrazTufts Medical Center Inc +[8] 
Active IndicationsAscitesAcute Kidney InjuryPulmonary Arterial Hypertension +[6] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)HypoxiaScleroderma, Systemic +[10] 

Other Information

ATC CodeC02KX02
Related LinksWikipediaDrugBankKEGG